Financial Comparison: NexGel (NASDAQ:NXGL) and Pressure BioSciences (OTCMKTS:PBIO)

NexGel (NASDAQ:NXGL) and Pressure BioSciences (OTCMKTS:PBIO) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, dividends, valuation and analyst recommendations.

Institutional and Insider Ownership

2.2% of NexGel shares are owned by institutional investors. Comparatively, 0.0% of Pressure BioSciences shares are owned by institutional investors. 20.6% of NexGel shares are owned by company insiders. Comparatively, 10.8% of Pressure BioSciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent ratings for NexGel and Pressure BioSciences, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NexGel	1	0	1	0	2.00
Pressure BioSciences	0	0	0	0	0.00

NexGel presently has a consensus price target of $2.00, indicating a potential upside of 211.53%. Given NexGel’s stronger consensus rating and higher probable upside, research analysts plainly believe NexGel is more favorable than Pressure BioSciences.

Profitability

This table compares NexGel and Pressure BioSciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
NexGel	-26.27%	-56.90%	-28.42%
Pressure BioSciences	N/A	N/A	N/A

Volatility and Risk

NexGel has a beta of 0.85, meaning that its stock price is 15% less volatile than the S&P 500. Comparatively, Pressure BioSciences has a beta of -0.8, meaning that its stock price is 180% less volatile than the S&P 500.

Valuation & Earnings

This table compares NexGel and Pressure BioSciences”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NexGel	$11.42 million	0.48	-$3.00 million	($0.38)	-1.69
Pressure BioSciences	$1.98 million	0.03	-$29.31 million	($0.96)	0.00

NexGel has higher revenue and earnings than Pressure BioSciences. NexGel is trading at a lower price-to-earnings ratio than Pressure BioSciences, indicating that it is currently the more affordable of the two stocks.

Summary

NexGel beats Pressure BioSciences on 10 of the 14 factors compared between the two stocks.

About NexGel

NEXGEL, Inc. manufactures high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels. Its products are used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was formerly known as AquaMed Technologies, Inc. and changed its name to NEXGEL, Inc. in November 2019. The company was incorporated in 2009 and is based in Langhorne, Pennsylvania.

About Pressure BioSciences

Pressure BioSciences, Inc. develops and sells pressure-based platform solutions in the North America, Europe, and Asia. The company's pressure cycling technology (PCT) technology uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control the actions of molecules in biological samples, including cells and tissues from human, animal, plant, and microbial sources. It offers Barocycler instrumentations comprising Barocycler 2320EXT, Barocycler HUB880, Barocycler HUB440, and the Shredder SG3. The company also distributes cell disruption equipment, parts, and consumables. In addition, it offers Barocycler consumable products, such as PCT MicroTubes, PCT MicroCaps, PCT-Micro Pestle, and pressure used to lyse samples for extraction tubes, as well as application specific kits, including consumable products and reagents. The company serves researchers at academic laboratories, government agencies, biotechnology companies, pharmaceutical firms, and other life science institutions. It has collaborations with RedShiftBio Inc.; Inova Schar Cancer Center; NYU; Leica Microsystems, GmbH; Steinbeis Centre for biopolymer analysis and biological mass spectrometry; The Ohio State University; University of Delaware; and Cedars Sinai Medical Center. The company was formerly known as Boston Biomedica, Inc. and changed its name to Pressure BioSciences, Inc. in September 2014. The company was incorporated in 1978 and is based in South Easton, Massachusetts.